A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

Cytomegalovirus Infection Clinical Trial

Official title:

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 When Administered to Healthy Japanese Adults (18-40 Years of Age) in the United States

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05105048
• Other study ID #: mRNA-1647-P103
• Status: Completed
• Phase: Phase 1
• Start date: November 8, 2021
• Est. completion date: August 10, 2023

Study information

• Verified date: September 2023
• Source: ModernaTX, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to evaluate the safety, reactogenicity, and immunogenicity of the mRNA-1647 vaccine administered according to a 3-study injection schedule in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive Japanese adults 18 to 40 years of age in the United States.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: August 10, 2023
• Est. primary completion date: August 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Participant is a Japanese Adult 18-40 years of age at the time of consent who, in the opinion of the investigator, is in good health based on review of medical history and screening physical examination. Japanese participants are defined as individuals born in Japan, with both parents and 4 grandparents who were born in Japan, and who have not lived outside of Japan for more than 10 years in total.
• For the CMV-seronegative groups: Participant is serum CMV IgG negative/ IgM negative.
• For the CMV-seropositive groups: Participant is either serum CMV IgG positive/IgM negative or IgG positive/IgM positive.
• Participant has a body mass index (BMI) from =18 kilograms (kg)/square meter (m^2) to =35 kg/m^2, inclusive.

Exclusion Criteria:

• History of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. Clinically unstable is defined as a diagnosis or condition requiring significant changes in management or medication within the 2 months prior to screening and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition.
• Participant has elevated liver function tests, defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP), or elevated creatinine or reduced platelets, with a toxicity score of Grade =1 at screening.
• Participant has laboratory test results (hematology, chemistry, and coagulation) with a toxicity score of Grade =1 at screening.
• Received or plans to receive any non-study vaccine <28 days prior to any study injection; in addition, the following criteria for COVID-19 and influenza vaccines apply: i. Any COVID-19 vaccination series must have been completed a minimum of 28 days prior to receiving any dose of the study injection. ii. COVID-19 vaccines (regardless of manufacturer) must be administered at least 28 days prior to or after any study injection. iii. Influenza vaccines may be administered >14 days prior to or after any study injection.
• Participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months before the day of first injection (Day 1) (for corticosteroids, >5 mg/day of prednisone equivalent) or plans to do so during the course of the study. Inhaled, nasal, and topical steroids are allowed.
• Participant has received an antiviral with activity against CMV (ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, acyclovir, valacyclovir) within 2 weeks before the first injection or plans to do so during the course of the study.
• Participant received any investigational CMV vaccine.
• History of myocarditis, pericarditis, or myopericarditis.
• Reported medical history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); or a positive screening test for hepatitis B surface antigen (HbSAg), hepatitis C antibodies, or HIV 1 or 2 antibodies. Other inclusion and exclusion criteria may apply.

Related Conditions & MeSH terms

• Cytomegalovirus Infection
• Cytomegalovirus Infections
• Infections

Intervention

Biological:
• mRNA-1647
Lyophilized product that is reconstituted with saline
• Placebo
0.9% sodium chloride (normal saline) injection

Locations

Country	Name	City	State
United States	East-West Medical Research Institute	Honolulu	Hawaii
United States	Velocity Clinical Research	North Hollywood	California
United States	California Research Foundation	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
ModernaTX, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)		Up to Day 176 (7 days after each injection)
Primary	Number of Participants With Unsolicited Adverse Events (AEs)		Up to Day 197 (28 days after each injection)
Primary	Number of Participants With Medically-Attended AEs (MAAEs)		Day 1 through 6 months after the last injection (up to Day 347)
Primary	Number of Participants With Serious AEs (SAEs)		Day 1 through End of Study (EOS) (up to Day 347)
Primary	Number of Participants With AEs of Special Interest (AESIs)		Day 1 through EOS (up to Day 347)
Secondary	Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies (nAbs) Against Epithelial Cell Infection and Against Fibroblast Infection		Days 1, 29, 85, 169, 197, and 347
Secondary	Geometric Mean Fold-Rise (GMFR) of nAb Against Epithelial Cell Infection and Against Fibroblast Infection		Days 29, 85, 169, 197, and 347
Secondary	Proportion of Participants with =2-Fold, 3-Fold, and 4-Fold Increases in nAb over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection		Days 29, 85, 169, 197, and 347
Secondary	GMT of Anti-Glycoprotein B (gB) Specific Immunoglobulin G (IgG) and Anti-Pentamer Specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)		Days 1, 29, 85, 169, 197, and 347
Secondary	GMFR of Anti-gB and Anti-Pentamer Specific IgG		Days 29, 85, 169, 197, and 347
Secondary	Proportion of Participants with =2-Fold, 3-Fold, and 4-Fold Increases Over Baseline in Anti-gB and Anti-Pentamer Specific IgG		Days 29, 85, 169, 197, and 347